Name:
|
Category
|
Manufacturer
|
Clinical Status & Links
|
4-1BBL
|
T-cell stimulator; apoptosis inhibitor
|
Immunex
|
preclinical
|
Anvirzel
|
broad immune enhancer, believed also to have antiangiogenic effects by some. Oleander extract
|
Ozelle Pharmaceuticals
|
Phase I trials
|
AS-101
|
broad immunomodulator increases IL-2 and IL-2 receptor. Organic tellurium salt
|
Wyeth-Ayerst
|
Phase II trials with Taxol
|
Atragen
Liposomal Tretinoin
|
differentiating retinoid direct anti-lyphoma/leukemia properties boosts NK function. More potent than free tretinoin
|
Aronex
|
phase II trials lymphoma/leukemia
|
Bropirimine
|
potent immunomodulator in bladder cancer, lymphoma, multiple IFN inducer
|
Remisar, Pharmacia & Upjohn
|
phase III trials
bladder cancer
|
C225
|
Anti-EGFr, humanized murine, monoclonal antibody
|
Imclone
|
Phase III trials
|
CD40 Ligand
|
Dendritic Cell activator
|
Immunex
|
phase I
|
Clarithromycin
|
antibiotic,increases NK counts (best when given a week after chemo)
|
|
approved for H. Pylori infections
|
CM101
|
potent antiangiogenic
|
Carbomed
|
Phase I trials
|
Cromolyn
|
Antiallergic, (mast cell inhibition) anecdotal antiangiogenic properties
|
Medeva
|
approved for allergies
|
Cytran IM-862
|
very small protein peptide
anti-angiogenic/
immune stimulating
|
Cytran
|
phase III
Kaposi's Sarcoma
|
FLT-3 ligand (Mobista)
|
bone marrow progenitor/dendritic cell growth factor/NK growth factor
|
Immunex
|
phase II trial
melanoma
|
GM-CSF (Leukine)
|
leukocyte proliferative cytokine/dendritic cell promoter. Might enhance Rituxan
|
Immunex
|
approved for low white counts
|
hLL2
|
Anti-CD22 humanized murine monoclonal antibody
|
Immunomedics
|
Phase II trials for NHL
|
Humune
|
Anti-CD20 Completely human monoclonal antibody
|
Intracell
|
preclinical
|
IDEC-Y2B8
(Zevalin)
|
Yttrium radiolabled Anti-CD20; humanized murine monoclonal antibody
|
IDEC pharmaceutical
|
approved for lymphoma
|
IL-12
|
Th1 cytokine
|
Genetics Institute
|
Phase I-II
|
IL-15
|
promotes NK cells and activates memory T cells muscle anabolic
|
Immunex
|
preclinical
|
IL-18
|
Th1 cytokine; Potent Interferon gamma inducer
|
|
investigative
|
IL-2
|
Th1 Cytokine
|
Chiron
|
Approved renal cell cancer
Testing in combination with Rituxan for NHL
|
IL-4 receptor (Nuvance)
|
TH2 inhibition
|
Immunex
|
Phase I trials Asthma
|
Imiquimod
|
Th1 inducing pharmaceutical
|
3M Pharmaceuticals
|
Phase I
terminated
|
Interferon Alpha 2b
|
anti-proliferative
MHC I enhancing cytokine
|
Schering-Plough
|
approved
|
interferon
(peginterferon alfa-2b)
|
as for interferon Alpha 2b, but encapsulated in liposome to reduce toxicity
|
Schering-Plough
|
full prescribing info
PEG-INF (new version) improves quality of life - peerviewpress
|
Interferon Gamma
|
Th1 cytokine
|
Genentech
|
phase I-II
AIDS/cancer
|
IP-10
|
anti-proliferative chemokine;
antiangiogenic T cell attractor
|
Invivogen
|
Phase I using gene vector in Europe
|
Linomide
|
promotes TGF-beta,NK cells, inhibits anti-body production.Potent antiangiogenic
|
|
Phase III Multiple Sclerosis trials terminated due to cardiovascular side effects.
|
Loxoribine
|
Th1 cytokines; increases NK activity, increases B cells
|
|
Phase I
|
Product R
(Reticulose)
|
broad immune enhancer, RNA protein conjugate
|
Advanced Viral Research Company
|
commonly used for flu throughout the 40's and 50's. removed from market by FDA citing inadequate research data
|
QS-21
|
broad immune enhancer. CD8 cell activator. Saponin compound derived from the soapbark tree Quillaja saponaria
|
Aquila
|
Phase III trials with vaccine for melanoma. numerous other trials
|
Rituximab/ Rituxan
|
Anti-CD20
Humanized mRNA monoclonal antibody
|
IDEC pharmaceutical
|
approved for lymphoma
|
SLC
|
chemokine recently discovered to have potent ant-cancer effects
|
|
investigative
|
Thymosin alpha (Zadaxin)
|
recombinant thymus peptide. increases IL-2 and IL-2 receptors on T-cells
|
SciClone Pharmaceuticals
|
Phase II trials in cancer to start this year, Phase II trials in Hepatitis C ongoing
|
Troponin-1
|
muscle protein with antiangiogenic effects
|
Boston Life Sciences
|
preclinical
|
Ukrain
|
Broad immune booster. Unusual alkylating agent and plant alkaloid conjugate
|
Ukrainian Anti- Cancer Insitute
|
trials in Russia and Austria
|
Virulizin
|
macrophage activator, derived from bovine bile
|
Lorus Therapeutics
|
Phase II trials pancreatic cancer
|
Z-100
|
cell wall extract from Mycobacterium Tuberculosis
|
|
clinical trials in Japan
|
